Randomised double-blind controlled trial of Perhexiline in heart failure with preserved ejection fraction syndrome (HFpEF)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN25678870

Enrollment

Registered

2010-05-12

Start date

2009-03-01

Completion date

Unknown

Last updated

2017-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Cardiovascular

Interventions

Perhexiline/placebo randomised in a 50:50 fashion. The perhexiline is started at 100 mg per oral twice daily (bd) and titrated according to serum levels. The medication is ceased after 3 months of the

Eligibility

Inclusion criteria

Inclusion criteria: Heart failure normal ejection fraction diagnosed by signs or symptoms of heart failure and limitation on metabolic exercise testing

Exclusion criteria

Exclusion criteria: 1. Renal or liver impairment 2. Atrial fibrillation 3. Contraindication to magnetic resonance imaging (MRI) 4. Contraindication to perhexiline

Design outcomes

Primary

Measure	Time frame
Peak oxygen consumption (VO2 max)	—

Secondary

Measure	Time frame
Symptomatic status (Modified Minnesota Living with Heart Failure Questionnaire)	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026